Immunology and Microbiology
Adjuvant
19%
Antibody Drug Conjugate
6%
Antibody-Dependent Cell-Mediated Cytotoxicity
27%
Antineoplastic Activity
8%
B Cell
38%
Basophil
46%
Basophil Activation
9%
Cancer Cell
8%
Cancer Tissue
38%
CD163
5%
Cell Killing
19%
Cell Membrane
19%
Cell Surface
19%
Chimeric Antigen Receptor T-Cell
6%
Chondroitin Sulfate Proteoglycan
76%
Disease Burden
38%
Effector Cell
11%
Fc Receptor
8%
Fragment Antigen-Binding
5%
Gamma Urogastrone
38%
Humoral Immunity
9%
Immune Response
12%
Immunocompetent Cell
11%
Immunoglobulin A
9%
Immunoglobulin E
100%
Immunoglobulin E Antibody
40%
Immunoglobulin G1
7%
Immunoglobulin G4
14%
Immunotherapy
60%
Interleukin 10
9%
Macrophage
15%
Melanoma Antigen
38%
Melanoma Cell
6%
Memory B Cell
9%
Mimotope
6%
Monoclonal Antibody
6%
Normal Human
23%
Pertuzumab
5%
Plasmablast
14%
Prevalence
6%
Programmed Death-Ligand 1
9%
Regulatory T Cell
5%
Survival Rate
19%
T Cell
5%
Tebentafusp
6%
Trastuzumab
38%
Tumor Cell
24%
Tumor Volume
19%
Type I Hypersensitivity
7%
Xenograft
15%
Medicine and Dentistry
Antifolate
7%
Cancer Tissue
38%
Cell Interaction
38%
Cell Surface
9%
Disease Burden
38%
Ex Vivo
7%
Folate Receptor 1
38%
Immune Response
9%
Immunoglobulin E
30%
Immunoglobulin E Antibody
38%
Immunosuppressive Drug
38%
Immunotherapy
38%
Macrophage
38%
Malignant Neoplasm
13%
Melanoma
38%
Neoplasm
57%
Ovarian Cancer
76%
Phase I Trials
7%
Proteochondroitin Sulfate
38%
Repolarization
38%
RNA Sequencing
7%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
38%
Folate Receptor 1
42%
Folic Acid Antagonist
7%
Immunoglobulin E
38%
Immunoglobulin E Antibody
38%
Immunotherapy
42%
Malignant Neoplasm
50%
Melanoma
38%
Monoclonal Antibody
8%
Neoplasm
19%
Ovary Cancer
38%
Proteochondroitin Sulfate
38%